Product
RSV MAT vaccine
1 clinical trial
1 indication
Indication
Respiratory Syncytial Virus InfectionsClinical trial
A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of AgeStatus: Completed, Estimated PCD: 2022-08-03